MedTrace Logo

Deep Brain Stimulation for Treatment Resistant Depression With the Medtronic Activa PC+S

NCT01984710 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-07-18

No results posted yet for this study

Summary

The goal of this study is to use the Activa Primary Cell + Sensing (PC+S) device to study Latent Field Potential (LFP) in the brains of people with Treatment Resistant Depression (TRD) before and during active stimulation. The ultimate goal is to understand the neural network that causes TRD and the changes that DBS cause in that network that results in the antidepressant effects.

Conditions

Interventions

DEVICE

Medtronic Activa PC+S System

Sponsors & Collaborators

  • Hope for Depression Research Foundation

    collaborator OTHER

  • The Dana Foundation

    collaborator OTHER

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • Emory University

    lead OTHER

Principal Investigators

  • Patricio Riva Posse, MD · Emory University

  • Helen Mayberg, MD · Emory University and Mount Sinai

  • Christopher Rozell, PhD · Georgia Institute of Technology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2029-01-31
Completion
2029-01-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01984710 on ClinicalTrials.gov